Comparison · NCT02914509-sae
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. OTX-TP (Sustained Release Travoprost) Intracanalicular Depot vs Placebo Vehicle (PV): serious adverse events. Trial comparisons, record NCT02914509-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02914509-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0201 | 0.00978 | 0.0409 | wilson | |
| Risk in group 2 | 0.0276 | 0.0127 | 0.059 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00753 | -0.0405 | 0.0181 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.727 | 0.248 | 2.14 | log | |
| Odds ratio, group 1 over group 2 | 0.722 | 0.239 | 2.18 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on OTX-TP (Sustained Release Travoprost) Intracanalicular Depot than on Placebo Vehicle (PV) | 133 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | OTX-TP (Sustained Release Travoprost) Intracanalicular Depot | Three hundred forty eight (348) subjects were randomized to OTX-TP | 7 | 348 | EG000 |
| Group 2 | Placebo Vehicle (PV) | Two hundred seventeen (217) subjects were randomized to the PV. | 6 | 217 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- through study duration, an average of 23 months
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
- NCT number
- NCT02914509
- Phases
- PHASE3
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Travoprost, Placebo Vehicle
- Lead sponsor
- Ocular Therapeutix, Inc.
- Results first posted
- 2021-10-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02914509?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02914509-sae